Loading...

Akinyemi Oni-Orisan, PharmD, PhD

TitleAssistant Professor
InstitutionUniversity of California San Francisco
DepartmentClinical Pharmacy
Address513 Parnassus Avenue
San Francisco CA 94117
Phone415-502-7551
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health records
    NIH K01HL143109Jul 15, 2018 - Jun 30, 2023
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. Association between the EPHX2 p.Lys55Arg Polymorphism and Prognosis Following an Acute Coronary Syndrome. Prostaglandins Other Lipid Mediat. 2018 Aug 07. PMID: 30096423.
      View in: PubMed
    2. Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics. 2018 May 25. PMID: 29793377.
      View in: PubMed
    3. Bai X, Mangum KD, Dee RA, Stouffer GA, Lee CR, Oni-Orisan A, Patterson C, Schisler JC, Viera AJ, Taylor JM, Mack CP. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. J Clin Invest. 2017 Feb 01; 127(2):670-680. PMID: 28112683.
      View in: PubMed
    4. Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR. Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res. 2016 Jan; 57(1):109-19. PMID: 26555503; PMCID: PMC4689337 [Available on 01/01/17].
    5. Oni-Orisan A, Lanfear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014 Sep-Oct; 22(5):193-8. PMID: 25093738; PMCID: PMC4329642.
    6. Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2014 Sep; 74:199-208. PMID: 24893205; PMCID: PMC4115045.
    7. Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH, Rodgers JE. Acute decompensated heart failure: evolving literature and implications for future practice. Pharmacotherapy. 2014; 34(4):373-88. PMID: 24214219.
      View in: PubMed
    8. Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, Lee CR. Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:67-73. PMID: 23000418.
      View in: PubMed
    9. Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab. 2012 Mar 01; 302(5):E500-9. PMID: 22185841; PMCID: PMC3311291.